- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04868669
Improving Maternal Nutrition in Matlab (IMNiM)
In-home, Intensive Nutrition Counseling to Improve Gestational Weight Gain in Rural Bangladesh: A Cluster-Randomized Controlled Trial
Background: Maternal undernutrition and inadequate gestational weight gain (GWG) are prevalent in rural communities of low- and middle-income countries (LMICs). In Matlab, Bangladesh, 54% of the women fail to gain adequate weight (>4 kg) in the third trimester. Risks associated with inadequate GWG include giving birth to a small-for-gestational age (SGA) infant, low birth weight (LBW) infant, preterm birth (PTB), etc. Few contemporary studies examined the efficacy of nutrition counseling on GWG improvement in LMICs.
Objectives: The primary objective of this study is to assess whether in-home, intensive nutrition counseling during pregnancy, compared to standard antenatal care, could improve GWG among pregnant women in rural Bangladesh.
Methods: This prospective, two-arm, parallel group, equal allocation, open-label, community-based, cluster-randomized controlled trial will be conducted in the icddr,b service area of Matlab, a rural subdistrict of Bangladesh. Clusters will be randomly allocated 1:1 to the intervention arm in which pregnant women will receive monthly in-home, intensive nutrition counseling or the control arm in which pregnant women will receive standard antenatal care as offered by icddr,b and Govt. facilities. Fixed Site Clinics (FSCs) located at the homes of the community health research workers (CHRWs) will act as clusters. Of the 33 FSCs serving rural areas in the icddr,b service area, 20 will be selected randomly and listed. These 20 clinics will then be randomly allocated 1:1 to either an intervention or control group using a computer-generated random allocation sequence. To fulfil the required sample size, each selected CHRW will enroll 16 consecutive pregnancies. Required sample size is 16 women per cluster i.e. 160 women per arm. Eligible participants will be enrolled upon obtaining their consent by 13 and 6/7 weeks of gestation (first trimester) and followed up to 6 weeks postpartum. Trained health workers will visit the homes of the women in the intervention arm once a month and provide nutrition counseling to the women and her influential family members such as mothers, mothers-in-law and husbands. Both intention-to-treat and per-protocol analyses will be performed.
Outcome measures/variables: Proportion of women with inadequate rate of weight gain in the second and third trimester of pregnancy according to the US Institute of Medicine (IOM) 2009 guidelines is the primary outcome variable.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Chandpur, Bangladesh
- International Centre for Diarrhoeal Disease Research, Bangladesh
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Pregnant women permanently residing in the icddr,b service area of Matlab fulfilling the following criteria:
Inclusion Criteria:
- aged 18-39 years
- in the first trimester of pregnancy (before 14 weeks of gestation)
- BMI 16-24.99 kg/m^2 measured on enrollment
- willing to participate in the study
Exclusion criteria
- multiple pregnancy (carrying two or more fetuses)
- threatened abortion, persistent pervaginal bleeding, or cervical incompetence
- history of three or more consecutive abortions
- history of gestational diabetes, macrosomia, gestational hypertension, preeclampsia/eclampsia in a prior pregnancy
- chronic diseases, such as hypertension, heart disease, chronic obstructive pulmonary disease, chronic kidney disease, chronic liver disease, pancreatic diseases, Crohn's disease, ulcerative colitis, diabetes mellitus, thyroid dysfunction, immunological diseases, malignancy or any other diseases which could impede compliance with the study protocol
- taking medications known to influence fetal growth, such as insulin, thyroid hormones, glucocorticoids
- known case of serious psychiatric or behavioral disorders, such as schizophrenia, bipolar disorder
- scored as moderate or worse on enrollment on any one of the subscales of the Depression, Anxiety and Stress Scales-21 (DASS-21)
- inability to read or write Bengali
- belonging to moderately or severely food insecure households as measured by the Household Food Insecurity Access Scale (HFIAS)
- having a plan to move or deliver outside the study area
- women practicing some form of vegetarianism
- women belonging to a household from which another woman is already enrolled in the study
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Pesquisa de serviços de saúde
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Intervention
In this arm, pregnant women, along with their influential family members such as mothers, mothers-in-law, and husbands, will receive monthly in-home, intensive nutrition counseling during the prenatal period.
|
|
Sem intervenção: Control
Pregnant women in this arm will receive standard antenatal care.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
proportion of women with inadequate rate of weight gain in the second and third trimester of pregnancy according to IOM 2009 guidelines
Prazo: Pre-delivery
|
Pregnancy trimesters are defined as follows: 1st trimester (0 weeks - 13+6 weeks), 2nd trimester (14 completed weeks - 27+6 weeks), and 3rd trimester (28 completed weeks - childbirth).
Rate of weight gain between two time points (trimesters) will be calculated by subtracting the weight measured at the first time point from the weight measured at the second time point and dividing the derived value by the difference in weeks between the two time points.
|
Pre-delivery
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
total gestational weight gain (kg)
Prazo: pre-delivery
|
pre-delivery
|
|
rate of weight gain during the 2nd and 3rd trimester (kg/week)
Prazo: pre-delivery
|
pre-delivery
|
|
proportion of women with inadequate total GWG according to IOM criteria
Prazo: pre-delivery
|
pre-delivery
|
|
proportion of women with inadequate total GWG according to local criteria
Prazo: pre-delivery
|
pre-delivery
|
|
proportion of women with inadequate third trimester weight gain according to local criteria
Prazo: pre-delivery
|
pre-delivery
|
|
proportion of preterm births
Prazo: at delivery
|
childbirth before 37 completed weeks
|
at delivery
|
maternal mid-upper arm circumference (MUAC) (mm)
Prazo: baseline, 36 weeks of gestation, at delivery and 6 weeks post-partum
|
baseline, 36 weeks of gestation, at delivery and 6 weeks post-partum
|
|
maternal weight (kg)
Prazo: baseline, 36 weeks of gestation, pre-delivery, at delivery and 6 weeks post-partum
|
baseline, 36 weeks of gestation, pre-delivery, at delivery and 6 weeks post-partum
|
|
maternal body mass index (BMI) (kg/m^2)
Prazo: baseline, 36 weeks of gestation, pre-delivery, at delivery and 6 weeks post-partum
|
weight and height (at baseline) will be combined to report BMI
|
baseline, 36 weeks of gestation, pre-delivery, at delivery and 6 weeks post-partum
|
infant weight (g)
Prazo: at birth (delivery) and after 4 weeks
|
at birth (delivery) and after 4 weeks
|
|
infant length (cm)
Prazo: at birth (delivery) and after 4 weeks
|
at birth (delivery) and after 4 weeks
|
|
infant head circumference (cm)
Prazo: at birth (delivery) and after 4 weeks
|
at birth (delivery) and after 4 weeks
|
|
proportion of low birth weight (< 2500 g) infants
Prazo: at birth (delivery)
|
at birth (delivery)
|
|
proportion of small for gestational age (<10th percentile) infants according to Intergrowth-21st standards
Prazo: at birth (delivery)
|
at birth (delivery)
|
|
proportion of women with pregnancy complications e.g. anemia, preeclampsia
Prazo: at delivery
|
at delivery
|
|
proportion of women with obstetric complications e.g. induction of labor, caesarean section
Prazo: at delivery
|
at delivery
|
|
newborn Apgar score
Prazo: at birth (delivery)
|
at birth (delivery)
|
|
proportion of infants developing morbidity
Prazo: 4 weeks after birth
|
4 weeks after birth
|
|
proportion of infant mortality
Prazo: 4 weeks after birth
|
4 weeks after birth
|
|
dietary diversity score according to the "Guidelines for Measuring Household and Individual Dietary Diversity"
Prazo: baseline, 36 weeks of gestation and 6 weeks post-partum
|
score range: 0-9; higher scores indicate a better outcome
|
baseline, 36 weeks of gestation and 6 weeks post-partum
|
dietary diversity score according to the "Minimum Dietary Diversity for Women: A Guide to Measurement"
Prazo: baseline, 36 weeks of gestation and 6 weeks post-partum
|
score range: 0-10; higher scores indicate a better outcome
|
baseline, 36 weeks of gestation and 6 weeks post-partum
|
proportion of women with inadequate dietary diversity accroding to the "Minimum Dietary Diversity for Women: A Guide to Measurement"
Prazo: baseline, 36 weeks of gestation and 6 weeks post-partum
|
score range: 0-10; <5 indicates inadequate dietary diversity
|
baseline, 36 weeks of gestation and 6 weeks post-partum
|
energy consumption (kcal)
Prazo: baseline, 36 weeks of gestation and 6 weeks post-partum
|
baseline, 36 weeks of gestation and 6 weeks post-partum
|
|
protein consumption (g)
Prazo: baseline, 36 weeks of gestation and 6 weeks post-partum
|
baseline, 36 weeks of gestation and 6 weeks post-partum
|
|
proportion of women with symptoms of depression as measured by Depression, Anxiety, and Stress Scales-21 (DASS-21) scales
Prazo: baseline, 36 weeks of gestation and 6 weeks post-partum
|
DASS-21 is a validated, widely used, standardized self-report scale with 7 items in each subscale category of Depression, Anxiety, and Stress symptoms.
Responses are scored on a 4-point Likert scale ranging from 0 (did not apply to me at all) to 3 (applied to me very much/most of the time), with higher scores indicating higher levels of depression, anxiety or stress.
|
baseline, 36 weeks of gestation and 6 weeks post-partum
|
proportion of women with symptoms of anxiety as measured by Depression, Anxiety, and Stress Scales-21 (DASS-21) scales
Prazo: baseline, 36 weeks of gestation and 6 weeks post-partum
|
DASS-21 is a validated, widely used, standardized self-report scale with 7 items in each subscale category of Depression, Anxiety, and Stress symptoms.
Responses are scored on a 4-point Likert scale ranging from 0 (did not apply to me at all) to 3 (applied to me very much/most of the time), with higher scores indicating higher levels of depression, anxiety or stress.
|
baseline, 36 weeks of gestation and 6 weeks post-partum
|
proportion of women with symptoms of stress as measured by Depression, Anxiety, and Stress Scales-21 (DASS-21) scales
Prazo: baseline, 36 weeks of gestation and 6 weeks post-partum
|
DASS-21 is a validated, widely used, standardized self-report scale with 7 items in each subscale category of Depression, Anxiety, and Stress symptoms.
Responses are scored on a 4-point Likert scale ranging from 0 (did not apply to me at all) to 3 (applied to me very much/most of the time), with higher scores indicating higher levels of depression, anxiety or stress.
|
baseline, 36 weeks of gestation and 6 weeks post-partum
|
healthcare seeking and services utilization e.g. number of prenatal visits
Prazo: at delivery
|
at delivery
|
Colaboradores e Investigadores
Investigadores
- Investigador principal: S. M. Tafsir Hasan, MBBS, MS, Nutrition and Clinical Services Division, icddr,b
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- PR-19109
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em In-home, intensive nutrition counseling
-
Gazi UniversityConcluídoExposição Ambiental | Desenvolvimento infantil | PrematuroPeru
-
The Hospital for Sick ChildrenCanadian Institutes of Health Research (CIHR); Unity Health Toronto; Mount Sinai... e outros colaboradoresConcluídoDeficiência de ferro não anêmicaCanadá